Demande de RDV
Venir à l'ICM
Faire un don
2024
- First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
- Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.
- Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
2023
- Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial. Quality of Life Research
- When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials. BMC Medical Research Methodology
- Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database. BMC Medicine
- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis. European Journal of Cancer
- Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic C
- Time-Dependent ROC Curve Analysis for Assessing the Capability of Radiation-Induced CD8 T-Lymphocyte Apoptosis to Predict Late Toxicities after Adjuvant Radiotherapy of Breast Cancer Patients. Cancers (Basel)
2022
- Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials
- The importance of using ordinal scores for patient classification based on health-related quality of life trajectories
- Clinical trials in Radiation Oncology: Methodologic approach
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
- Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial
Publications
Retrouvez sur le lien suivant l'ensemble des publications relatives à la Direction de la recherche clinique et de l'innovation (DRCI).